temozolomide has been researched along with risperidone in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T | 1 |
Chen, Z; Gao, Y; Li, Y; Lin, J; Lu, N; Wan, Q; Wang, H; Wang, Q; Wang, T; Yang, J; Ye, Y; Zhao, B; Zhao, K | 1 |
1 review(s) available for temozolomide and risperidone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for temozolomide and risperidone
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Damage; Dopamine D2 Receptor Antagonists; Drug Synergism; Glioblastoma; Haloperidol; Histones; Humans; In Vitro Techniques; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Receptors, Dopamine D2; Risperidone; RNA, Messenger; Temozolomide | 2019 |
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Risperidone; Temozolomide; TNF Receptor-Associated Factor 4; Ubiquitin-Protein Ligases; Ubiquitin-Specific Peptidase 7; Ubiquitins | 2022 |